OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

September 22nd 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors

September 22nd 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

Dr Di Federico on an Analysis of TTF-1 Expression in Lung Adenocarcinoma

September 22nd 2023

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.

Dr Qin on Ongoing Investigations of Belzutifan Combinations in Advanced ccRCC

September 22nd 2023

Qian (Janie) Qin, MD, discusses several belzutifan combination strategies under investigation in advanced clear cell renal cell carcinoma.

Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast Cancer

September 22nd 2023

Judy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.

Dr Zhang on the Use of Radiation Therapy for Oligometastatic RCC

September 22nd 2023

Tian Zhang, MD, MHS, discusses the use of radiation therapy for patients with oligometastatic renal cell carcinoma.

Dr Esteva on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

September 22nd 2023

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC

September 22nd 2023

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian Cancer

September 21st 2023

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.

Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AML

September 21st 2023

Johannes Schetelig, MD, MSc, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).

Dr Seymour on Patient Subsets That May Benefit From Curative FCR in CLL

September 21st 2023

John Seymour, MBBS, FRACP, PhD, discusses the characteristics of patient subgroups with chronic lymphocytic leukemia who may benefit from curative treatment with fludarabine, cyclophosphamide, and rituximab.

Dr Camidge on the Rationale for the TRUST-II Trial in ROS1+ NSCLC

September 20th 2023

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.

Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FL

September 20th 2023

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC

September 20th 2023

Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

September 20th 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FL

September 20th 2023

Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.

Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

September 20th 2023

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML

September 20th 2023

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

Dr Pothuri on Treating Patients With Ovarian Cancer

September 19th 2023

Bhavana Pothuri, MD, discusses treatment considerations for patients in tough-to-treat subgroups of ovarian cancer based on currently available data.

Dr Nastoupil on the Use of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 19th 2023

Loretta J. Nastoupil, MD, discusses the rationale for investigating the use of lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.